PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
7.01%
Some net income increase while TRAW is negative at -19.10%. John Neff would see a short-term edge over the struggling competitor.
8.54%
D&A growth of 8.54% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
100.00%
Well above TRAW's 100.00% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
48.65%
SBC growth well above TRAW's 0.30%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-142.09%
Negative yoy working capital usage while TRAW is 138.14%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-124.49%
Negative yoy AP while TRAW is 279.40%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-84.29%
Both reduce yoy usage, with TRAW at -1271.70%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
47.93%
Some yoy increase while TRAW is negative at -169.97%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
1.55%
Operating cash flow growth above 1.5x TRAW's 0.14%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1131.77%
Issuance growth of 1131.77% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.